Essential Thrombocythemia Et clinical trials

Explore recruiting essential thrombocythemia et clinical trials.

Recruiting essential thrombocythemia et studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Essential Thrombocythemia Et trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

I3X-MC-JHTB: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Spain, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

France

Phase II and Phase III (Integrated) EU CTIS Study details

Essential Thrombocythemia Et trials by city

Essential Thrombocythemia Et clinical trials

Recruiting essential thrombocythemia et studies right now

Efficacy and Safety of Peginterferon in ET and PV.

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Also recruiting in Europe

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

I3X-MC-JHTB: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

Essential Thrombocythemia Et trials by city

Other conditions